Evidence map›Paper›PMID 39214083›Full record

Trial reportCell reports. Medicine2024

Impact of antimicrobials on penile HIV susceptibility and immunology in uncircumcised men: A randomized phase 1/2 clinical trial.

Ronald M Galiwango, Brenda Okech, Daniel E Park, Lane Buchanan, Zhongtian Shao, Bernard Bagaya, Juliet Mpendo, Vineet Joag, Sergey Yegorov, Annet Nanvubya and 13 more

Abstract readClinical Trial, Phase IIRandomized Controlled TrialClinical Trial, Phase I
In one paragraph

Trial report in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. HIV Transmission and Immunology of the Male Reproductive Tract.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  2. Article
  3. Anaerobe-Driven Inflammation and Epithelial Barrier Disruption in Genital HIV Acquisition.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. UnveilingiScience · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ronald M GaliwangoDepartments of Medicine and Immunology, University of Toronto, Toronto, ON M5S1A8, Canada.
Brenda OkechUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Daniel E ParkDepartment of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA.
Lane BuchananDepartments of Microbiology and Immunology and Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON N6A3K7, Canada.
Zhongtian ShaoDepartments of Microbiology and Immunology and Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON N6A3K7, Canada.
Bernard BagayaUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda; Department of Microbiology, Makerere University College of Health Sciences, Kampala, Uganda.
Juliet MpendoUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Vineet JoagDepartments of Medicine and Immunology, University of Toronto, Toronto, ON M5S1A8, Canada; Centre for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Sergey YegorovDepartments of Medicine and Immunology, University of Toronto, Toronto, ON M5S1A8, Canada; McMaster University, Institute for Infectious Disease Research, Guelph, ON L8S4L8, Canada.
Annet NanvubyaUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Victoria M BiribawaUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Teddy NamatovuUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Charles KatoUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Barbara KawoozoUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Ali SsetaalaUVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
Moses MuwangaEntebbe General Hospital, Entebbe, Uganda.
Maliha AzizDepartment of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA.
Tony PhamDepartment of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA.
Sanja HuibnerDepartments of Medicine and Immunology, University of Toronto, Toronto, ON M5S1A8, Canada.
Aaron A R TobianDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Cindy M LiuDepartment of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA.
Jessica L ProdgerDepartments of Microbiology and Immunology and Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON N6A3K7, Canada.
Rupert KaulDepartments of Medicine and Immunology, University of Toronto, Toronto, ON M5S1A8, Canada; Department of Medicine, University Health Network, Toronto, ON M5G2C4, Canada. Electronic address: rupert.kaul@utoronto.ca.

Funding

The role of penile bacteria and inflammation in HIV susceptibility; Rakai, UgandaR01AI123002 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LIU, CINDY · 2016 to 2020
$3.3M
How sex, host microenvironment, and immune responses shape acquisition of genital bacteria that increase HIV riskR01DK131936 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Cindy Liu · 2022 to 2026
$3.0M
Male Circumcision and Use of Foreskin Tissues for HIV Prevention in UgandaD43TW009578 · FIC · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2013 to 2017
$1.3M
FIC NIH HHS D43 TW009578NIAID NIH HHS R01 AI123002NIDDK NIH HHS R01 DK131936
6 · The paper itself

Abstract

Within the penile microbiome, bacteria associated with seroconversion, immunology, and cells (BASIC species) enhance HIV susceptibility in heterosexual uncircumcised men by inducing foreskin inflammation and HIV target cell recruitment. This phase 1/2 clinical trial randomizes HIV-uninfected Ugandan men (n = 125) to either oral tinidazole, topical metronidazole, topical clindamycin, or topical hydrogen peroxide to define impact on ex vivo foreskin HIV susceptibility, penile immunology, and BASIC species density. Antimicrobials are well tolerated, and 116 (93%) participants complete the protocol. Topical metronidazole and oral tinidazole reduce the inner foreskin tissue density of HIV-susceptible CD4

Indexed as

HIV InfectionsPenisAdultAnti-Infective AgentsCD4-Positive T-LymphocytesCircumcision, MaleDisease SusceptibilityForeskinHumansMaleMetronidazoleUgandaYoung AdultAnti-Infective AgentsMetronidazoleantimicrobialsclinical trialgenital immunologyHIV transmissionpenile microbiomeUganda

Identifiers

PMID39214083
PMCPMC11536468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.